

November 10, 2016

National Stock Exchange of India Ltd.,  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E)  
Mumbai – 400 051

Symbol : AMRUTANJAN

Tel No: (022) 26598100

Fax No: (022) 26598120

Dear Sirs,

**Outcome of the Board Meeting – Clause 33 read with Clause 30(6) of SEBI (LODR) Regulations, 2015**

Kindly note that the Board of Directors of the Company at its meeting held today at the Registered Office of the Company had inter-alia:

- a. Approved the Unaudited standalone Financial Results for the quarter/half yearly ended 30<sup>th</sup> September, 2016. The same together with the Limited Review Report of the Statutory Auditors of the Company are attached;
- b. Declared 1<sup>st</sup> Interim Dividend of Rs. 1.10/- per share for the year 2016-2017 on the Equity Shares of the Company.


The Board Meeting commenced at 11.15 A.M. and concluded at 2.45 P.M.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Amrutanjan Health Care Limited

  
(M. Srinivasan)

Company Secretary & Compliance Officer

✓ CC :

DCS-CRD  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
MUMBAI – 400 001

Fax # 022-22723121/ 22722037  
22722041/ 22723719  
22722039/ 22722061

## AMRUTANJAN HEALTH CARE LIMITED

REGD. OFFICE : NEW NO.103 (OLD NO. 42-45), LUZ CHURCH ROAD, MYLAPORE, CHENNAI - 600 004.  
email id : investors@amrutanjan.com; website : www.amrutanjan.com; CIN No : L24231TN1936PLC000017  
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / HALF YEAR ENDED 30th SEP 2016

(Rs. In Lakhs)

Sl No.	Particulars	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30-Sep-16	30-Jun-16	30-Sep-15	30-Sep-16	30-Sep-15	31-Mar-16
		(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(Audited)
<b>PART - I</b>							
	<b>Gross Sales</b>	5,772.68	3,600.60	4,705.70	9,373.28	7,706.17	19,192.25
	Less : Excise Duty	295.28	160.10	233.44	455.38	360.58	882.33
1.	(a) Net Sales / Income from operations	5,477.40	3,440.50	4,472.26	8,917.90	7,345.59	18,309.92
	(b) Other Operating Income	43.46	27.48	32.38	70.94	68.57	127.76
	<b>Total Income</b>	5,520.86	3,467.98	4,504.64	8,988.84	7,414.16	18,437.68
2.	<b>Expenditure</b>						
a.	(Increase) / Decrease in Stock in Trade and work in progress	(97.39)	(327.24)	(10.21)	(424.63)	(220.02)	33.67
b.	Consumption of raw & other materials	1,720.29	1,590.01	1,334.29	3,310.30	2,557.70	5,858.90
c.	Purchase of Traded goods	259.79	278.31	141.92	538.10	326.58	626.80
d.	Employee Cost	762.92	783.30	707.68	1,546.22	1,311.16	2,801.22
e.	Advertisement & Selling Expenditure	903.41	268.18	692.12	1,171.59	1,056.59	2,967.19
f.	Depreciation	59.41	63.02	53.38	122.43	112.04	252.46
g.	Other Expenditure	832.76	617.95	697.77	1,450.71	1,233.97	2,987.89
	<b>Total Expenditure</b>	4,441.19	3,273.53	3,616.95	7,714.72	6,378.02	15,528.13
3.	<b>Profit from Operations before Other income, Interest and Exceptional Items (1 - 2)</b>	1,079.67	194.45	887.69	1,274.12	1,036.14	2,909.55
4.	Other Income	112.60	113.59	190.13	226.19	300.57	554.80
5.	<b>Profit before Interest and Exceptional Items (3 + 4)</b>	1,192.27	308.04	1,077.82	1,500.31	1,336.71	3,464.35
6.	Interest	3.14	5.52	3.78	8.66	3.92	8.16
7.	<b>Profit after Interest but before Exceptional Items (5 - 6)</b>	1,189.13	302.52	1,074.04	1,491.65	1,332.79	3,456.19
8.	Exceptional items	-	-	-	-	-	-
9.	<b>Profit from Ordinary Activities before Tax (7 + 8)</b>	1,189.13	302.52	1,074.04	1,491.65	1,332.79	3,456.19
10.	Tax Expense incl Deferred Tax	394.55	91.95	341.49	486.50	429.91	1,214.41
11.	<b>Net Profit from Ordinary Activities after Tax (9 - 10)</b>	794.58	210.57	732.55	1,005.15	902.88	2,241.78
12.	Extraordinary Items :	-	-	-	-	-	-
13.	<b>Net Profit for the Period (11 + 12)</b>	794.58	210.57	732.55	1,005.15	902.88	2,241.78
14.	Paid-up Equity Share Capital (Face Value Rs 2 /- (Rs. 2/- each)	292.31	292.31	292.31	292.31	292.31	292.31
15.	Reserve excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	10,192.20
16.	<b>Earnings Per Share EPS - Rs. (Not Annualised)</b>						
	a) Basic and diluted EPS before Extraordinary items (Rs )	5.44	1.44	5.01	6.88	6.18	15.34
	b) Basic and diluted EPS after Extraordinary items (Rs )	5.44	1.44	5.01	6.88	6.18	15.34

<b>PART - II</b>							
<b>A. Particulars of Shareholding</b>							
1.	<b>Public Shareholding</b>						
	Number of Shares	7281770	7281770	7240270	7181770	7240270	7240270
	Percentage of shareholding	49.82%	49.82%	49.54%	49.82%	49.54%	49.54%
2.	<b>Promoters and Promoter Group Shareholding</b>						
	a) Pledged / Encumbered						
	- Number of shares						
	- Percentage of shares (as a % of the total share capital of the company)						
	b) Non-encumbered						
	- Number of shares	7333545	7333545	7375045	7333545	7375045	7375045
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	50.18%	50.18%	50.46%	50.18%	50.46%	50.46%

<b>B. INVESTOR COMPLAINTS</b>		for the Quarter ended 30th Sep 2016
Pending at the beginning of the quarter		Nil
Received during the quarter		2
Disposed off during the quarter		2
Remaining unresolved at the end of the quarter		Nil

**Notes**

2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its Meeting held on 10th November, 2016
3. The statutory auditors have carried out a limited review of the above financial results.
4. The figures for the previous quarter / period have been regrouped / reclassified wherever necessary.

For Amrutanjan Health Care Limited



S. Sambhu Prasad  
Chairman & Managing Director

Place : Chennai  
Date : 10th Nov 2016

**AMRUTANJAN HEALTH CARE LIMITED**

REGD. OFFICE : NEW NO.103 (OLD NO. 42-45), LUZ CHURCH ROAD, MYLAPORE, CHENNAI - 600 004

email : investors@amrutanjan.com; website : www.amrutanjan.com; CIN No : L74231181936PLC060917

**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / HALF YEAR ENDED 30th SEP 2016**

(Rs. In Lakhs)

**Segmentwise Revenue, Results and Capital Employed  
under Clause 41 of the Listing Agreement**

Particulars	STANDALONE					
	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
	30-Sep-16 (unaudited)	30-Jun-16 (unaudited)	30-Sep-15 (unaudited)	30-Sep-16 (unaudited)	30-Sep-15 (unaudited)	31-Mar-16 (Audited)
<b>1 Segment Revenue</b>						
Net Sales						
a) OTC Products	5,138.28	2,553.67	4,178.34	7,691.95	6,250.08	16,138.50
b) Beverages	339.12	886.83	293.92	1,226.95	1,095.51	2,171.42
c) APMC	43.46	27.48	32.38	70.94	68.57	127.76
<b>Total</b>	<b>5,520.86</b>	<b>3,467.98</b>	<b>4,504.64</b>	<b>8,988.84</b>	<b>7,414.16</b>	<b>18,437.68</b>
Less: Inter segment revenue	-	-	-	-	-	-
<b>Sales / Income from operations</b>	<b>5,520.86</b>	<b>3,467.98</b>	<b>4,504.64</b>	<b>8,988.84</b>	<b>7,414.16</b>	<b>18,437.68</b>
<b>2 Segment Results</b>						
<b>Profit/(Loss) Before Tax and Interest</b>						
a) OTC Products	1,323.21	355.19	1,135.76	1,678.40	1,346.33	3,542.32
b) Beverages	(128.69)	(114.38)	(86.05)	(243.07)	(92.89)	(245.74)
c) APMC	(56.93)	(32.48)	(39.13)	(89.41)	(78.19)	(165.55)
<b>Total</b>	<b>1,137.59</b>	<b>208.33</b>	<b>1,010.58</b>	<b>1,345.92</b>	<b>1,175.25</b>	<b>3,131.03</b>
Less: a) Interest	3.14	5.52	3.78	8.66	3.92	8.16
b) Other un-allocable expenditure net off unallocable income	(64.68)	(99.71)	(67.24)	(154.39)	(161.46)	(333.32)
Less: Exceptional items	-	-	-	-	-	-
Add: Extraordinary items	-	-	-	-	-	-
<b>Total Profit Before Tax</b>	<b>1,189.13</b>	<b>302.52</b>	<b>1,074.04</b>	<b>1,491.65</b>	<b>1,332.79</b>	<b>3,456.19</b>
<b>3 Segment Assets</b>						
a) OTC Products	9,211.69	8,181.49	7,494.77	9,211.69	7,494.77	8,358.16
b) Beverages	1,641.97	1,778.89	1,469.57	1,641.97	1,469.57	1,357.39
c) APMC	33.58	34.77	37.39	33.58	37.39	35.90
d) Unallocated	5,052.65	5,144.12	4,825.50	5,052.65	4,825.50	5,122.08
<b>Total</b>	<b>15,939.89</b>	<b>15,139.27</b>	<b>13,827.23</b>	<b>15,939.89</b>	<b>13,827.23</b>	<b>14,873.53</b>
<b>4 Segment Liabilities</b>						
a) OTC Products	2,096.66	1,969.44	1,747.23	2,096.66	1,747.23	1,949.10
b) Beverages	427.40	795.08	345.83	427.40	345.83	541.20
c) APMC	-	-	-	-	-	-
d) Unallocated	362.91	116.39	346.78	362.91	346.78	335.46
<b>Total</b>	<b>2,886.97</b>	<b>2,880.91</b>	<b>2,439.84</b>	<b>2,886.97</b>	<b>2,439.84</b>	<b>2,825.76</b>

Notes :

**1. STATEMENT OF ASSETS AND LIABILITIES**

(Rs. In Lakhs)

PARTICULARS	AS ON 30-SEP-2016	AS ON 31-MAR-2016
	UNAUDITED	AUDITED
<b>A) Shareholders' funds</b>		
a) Shareholders funds	292.31	292.31
b) Reserve and surplus	12,760.61	11,756.46
<b>Sub-total - Shareholders funds</b>	<b>13,052.92</b>	<b>12,047.77</b>
<b>2) Non-Current liabilities</b>		
a) Long-term borrowings	-	-
b) Deferred tax liabilities (net)	177.89	191.39
c) Other Long-term liabilities	41.96	41.96
d) Long-term Provisions	72.84	73.03
<b>Sub-total - Non-Current liabilities</b>	<b>292.69</b>	<b>306.40</b>
<b>3) Current liabilities</b>		
a) Short-term borrowings	-	-
b) Trade payables	998.04	907.21
c) Other current liabilities	1,484.05	1,429.63
d) Short-term provisions	112.18	182.52
<b>Sub-total - Current liabilities</b>	<b>2,594.27</b>	<b>2,519.36</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>15,939.88</b>	<b>14,873.53</b>
<b>B) ASSETS</b>		
<b>1) Non-current Assets</b>		
a) Fixed assets incl CWP	2,622.05	2,321.61
b) Investments / Derivatives	903.84	587.47
c) Long-term loans and advances	2,064.45	1,971.05
d) Other non-current assets	131.14	132.62
<b>Sub-total - Non-current Assets</b>	<b>5,721.48</b>	<b>5,402.71</b>
<b>2) Current assets</b>		
a) Current investments	-	-
b) Inventories	1,298.54	799.78
c) Trade receivables	1,961.43	2,617.75
d) Cash and cash equivalents	5,517.35	4,795.31
e) Short-term loans and advances	1,056.65	899.68
f) Other Current assets	384.43	362.30
<b>Sub-total - Current Assets</b>	<b>10,218.40</b>	<b>9,465.82</b>
<b>TOTAL ASSETS</b>	<b>15,939.88</b>	<b>14,873.53</b>

For Amrutanjan Health Care Limited



S. Sambhu Prasad  
Chairman & Managing Director

Place : Chennai

Date : 10th Nov 2016



## Highlights of Q2 results

- Gross sales of the Company have increased from Rs. 77.06cr. to Rs. 93.73 Cr. ( 21.63 % Growth )
- Profit Before Tax has increased from Rs. 13.32 Cr. to Rs. 14.92 Cr. ( 12 % increase)
- Profit after Tax has increased from Rs. 9.03 Cr to Rs. 10.02 Cr. ( 11 % increase )
- Earnings per share has gone up from 6.18 of last year to 6.88 ( 11 % increase

### OTC Division

- Gross sales of OTC have increased from Rs. 65.99 cr. To Rs. 81.36 Cr. (Increase of Rs. 15.37 Cr out of which Rs. 13.21 Cr. came from Volume growth). 23.29% Growth out of which volume growth is 20.02 %
- Volume of 302.26 Tons. Sold in H1 of 2016-17 as against 250.44 Tons during H1 of 2015-16.

### Fruitnik Division

- Gross Sales increased from Rs. 11.14 Cr. to Rs. 12.46 Cr. for YTD Sep ( 11.85 % increase over last year same period )
- ATL Spend has been increased from Rs. 24 Lakhs to Rs. 78 lakhs.
- Fruitnik division sales is lower than expected in H1 as the Eastern region plant came online later than the expected time line.

## The salient point of the Outcome of the Board Meeting

The Company have been paying dividend twice a year so far and It has been decided to distribute the dividend across the year paying interim dividend more than once preferably every quarter. It has been decided to pay Rs. 1.10 per share of face value Rs. 2.00 as interim dividend with the book closure date as 18<sup>th</sup> November 2016.



# P. S. SUBRAMANIA IYER & CO.

CHARTERED ACCOUNTANTS

New No. 103, (Old No. 57/2), P. S. Sivasamy Salai, (Sullivan Garden Road), Mylapore, Chennai - 600 004.

Phone : 2499 2449 / 2499 2470

E-mail : pssco\_2000@yahoo.com pssandco@gmail.com

## LIMITED REVIEW REPORT

The Board of Directors,  
Amrutanjan Health Care Limited,  
New No.103 Luz Church Road,  
Chennai-600004.

We have reviewed the accompanying statement of unaudited financial results of Amrutanjan Health Care Limited ('the Company') for the period ended 30<sup>th</sup> September, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Engagements to Review Financial statements" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financials statements are free of material misstatement. A review is limited primarily to enquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements)Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Chennai  
Date : 10.11.2016

For P.S.Subramania Iyer & Co.,  
Chartered Accountants  
Firm Registration No : 004104S

V.Swaminathan  
Partner

Membership No : 22276

